Our findings suggest that the regression of cystic renal disease is not a universal phenomenon of TORC1 inhibition in PKD, and at the very least drug therapy must be initiated at the earliest stages of kidney enlargement in order to gain the maximal absolute lifetime benefit on TKV reduction. This evidence concerns the gene CRTC1 and cystic kidney disease.